RAD50 mutation	Solid Tumor	RAD50 mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
RAD50 mutation	Small Cell Lung Cancer	RAD50 mutation	Small Cell Lung Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
RAD50 mutation	Colon Cancer	RAD50 mutation	Colon Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
RAD50 mutation	Prostate Cancer	RAD50 mutation	Prostate Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
RAD50 Y625	Prolymphocytic Leukemia	RAD50 Y625	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
RAD50 I371Ffs*8	Ovarian Cancer	RAD50 I371Ffs*8	Ovarian Cancer	bevacizumab + pamiparib Sensitive: C4 – Case Studies bevacizumab + pamiparib Sensitive : C4	bevacizumab + pamiparib Sensitive: C4 – Case Studies bevacizumab + pamiparib Sensitive : C4
RAD50 deletion	Breast Cancer	RAD50 deletion	Breast Cancer	niraparib Sensitive: D – Preclinical niraparib Sensitive : D	niraparib Sensitive: D – Preclinical niraparib Sensitive : D
RAD50 deletion	Breast Cancer	RAD50 deletion	Breast Cancer	rucaparib Sensitive: D – Preclinical rucaparib Sensitive : D	rucaparib Sensitive: D – Preclinical rucaparib Sensitive : D

RAD50 (RAD50 Double Strand Break Repair Protein)

Associations(8)

Associations
(8)